Clinical trials: Genital Neoplasm, Female
Ovarian Cancer, Clinical Marker
The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer
Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy. PARP inhibitors(PARPi) are an important progress in EOC treatment.
- Conditions
- Ovarian Cancer, Clinical Marker, PARP Inhibitor
- Trial name
- ROMP (NCT04582552)
- Testing
- PARP inhibitors
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xiaoxiang Chen
Neoplasm Malignant, Breast Cancer
Shorter Scalp Cooling Time in Paclitaxel
Chemotherapy-induced alopecia (CIA) is one of the most distressing side effects for patients. Scalp cooling can prevent or minimise CIA in approximately half of all patients, depending on many factors, e.g.
- Conditions
- Neoplasm Malignant, Breast Cancer, Ovarian Cancer
- Trial name
- COP (NCT03266185)
- Testing
- Shorter PICT
- Where
- Netherlands
- Volunteers
- 91 people
- Sponsor
- Leiden University Medical Center
Uterine Cervical Neoplasms
Role of Bladder Training During Post-operative Hospital Stay After Radical Hysterectomy in Patients
The objective of the study is to evaluate the impact and the outcome of bladder training during post-operative hospital stay after radical hysterectomy, mainly after neoadjuvant concurrent chemo-radiation therapy for locally…
- Trial name
- NCT01907646
- Testing
- bladder training, No bladder training
- Where
- Italy
- Volunteers
- 111 people
- Sponsor
- Catholic University of the Sacred Heart
Endometrial Cancer
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2…
- Trial name
- NCT07022483
- Testing
- Trastuzumab Deruxtecan, Chemotherapy
- Where
- 86 sites in United States, Argentina and 13 more
- Volunteers
- 710 people
- Sponsor
- Daiichi Sankyo
Cancer
Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation
RATIONALE: Giving itraconazole or fluconazole may be effective in preventing infections in patients undergoing peripheral stem cell or bone marrow transplantation.
- Trial name
- NCT00003883
- Testing
- fluconazole, itraconazole
- Where
- 2 sites in United States
- Volunteers
- 578 people
- Sponsor
- Fred Hutchinson Cancer Center
Uterine Cancer
Uterine Papillary Serous Cancer (UPSC) Trial
This study will be an open, non-randomised, clinical phase 2 trial, which will involve 30 women diagnosed with uterine papillary serous cancer.
- Trial name
- NCT00147680
- Testing
- Paclitaxel, Carboplatin
- Where
- 2 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Queensland Centre for Gynaecological Cancer
Cervical Cancer, Cancer
The Association Between Cervical Cancer Screening and Cancer Occurrence
To investigate the protective effect of cervical cancer incidence and mortality by screening attending frequency or screening pattern, and to evaluate the possible risk of developing malignancies among women with cervical…
- Trial name
- NCT01015079
- Where
- Taiwan
- Volunteers
- 6,000,000 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Ovarian Cancer
Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer
The purpose of this study is to evaluate whether or not the addition of Herceptin may be of benefit to a standard regimen of carboplatin-paclitaxel.
- Trial name
- NCT00189579
- Testing
- Herceptin
- Where
- France
- Volunteers
- 45 people
- Sponsor
- ARCAGY/ GINECO GROUP
Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor
Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
This phase I trial is studying the side effects and best dose of polyglutamate paclitaxel when given together with carboplatin in treating patients with ovarian epithelial, peritoneal, or fallopian tube cancer.
- Conditions
- Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma
- Trial name
- NCT00060359
- Testing
- Carboplatin, Paclitaxel Poliglumex, Pharmacological Study
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Gynecologic Oncology Group
Cervical Cancer, Neoadjuvant Chemoimmunotherapy
Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer
This multicenter, prospective clinical trial is designed to enroll PD-L1 expression-positive patients with stage IB1 cervical cancer who desire fertility preservation to undergo neoadjuvant chemotherapy in combination with a PD-1…
- Conditions
- Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Fertility Preservation
- Trial name
- NCT06289062
- Testing
- Camrelizumab, Cisplatin, Nab paclitaxel
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Tongji Hospital
Intraepithelial Neoplasia, Cervical Cancer
NWRD09 for HPV-16 Positive and HPV-16 Related Intraepithelial Neoplasia and Cervical Cancer Patients.
This is a single-arm, open label, two cohorts, multi-center clinical study to evaluate the safety and efficacy of HPV-16 targeted mRNA vaccine (NWRD09) in HPV-16 positive and HPV-16 related cervical, vaginal, and vulvar…
- Trial name
- NCT06741150
- Testing
- NWRD09 administered by intramuscular injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Newish Technology (Beijing) Co., Ltd.
Metastatic Malignant Female Reproductive System Neoplasm, Platinum-Resistant Malignant Female Reproductive System Neoplasm
Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies
This phase II trial studies the side effects and how well brachytherapy with durvalumab or tremelimumab work for the treatment of gynecological malignancies that is resistant to platinum therapy (platinum-resistant), does not…
- Conditions
- Metastatic Malignant Female Reproductive System Neoplasm, Platinum-Resistant Malignant Female Reproductive System Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Refractory Malignant Female Reproductive System Neoplasm
- Trial name
- NCT04395079
- Testing
- Durvalumab, Internal Radiation Therapy, Tremelimumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Ovarian Neoplasms
Study of T900607-Sodium in Previously Treated Patients With Ovarian Cancer.
The purpose of this study is to determine whether T900607-sodium is effective and safe in treating ovarian cancer.
- Trial name
- NCT00043446
- Testing
- intravenous T900607-sodium
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Tularik
Polycystic Ovary Syndrome
Living With Polycystic Ovary Syndrome
This project aims to develop and pilot an evidence-based structured education program that can be run in groups to enable women with PCOS to make lifestyle changes, which will help them improve their PCOS and reduce the risk of…
- Trial name
- LW-PCOS (NCT04777461)
- Testing
- Survey on patient's perspectives on the development of an structured education programme for PCOS, Pre-pilot questionnaire, Piloting the structured education programme for PCOS
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Hull
Breast Reconstruction, Breast Cancer
Evaluation of Well Being and Patient Reported Outcomes After Robotic Single-port Nipple Sparing Mastectomy and Implant Reconstruction
This study is being carried out to better understand how different types of mastectomy surgeries affect women's recovery, satisfaction, and overall well-being after breast cancer surgery and reconstruction.
- Conditions
- Breast Reconstruction, Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2), Robotic Surgery
- Trial name
- Reborn-i (NCT07236359)
- Testing
- Intervention, Standard open nipple sparing mastectomy with immediate implant-based reconstruction
- Volunteers
- 108 people
- Sponsor
- Beaumont Hospital
Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Randomized, 2-arm observational study. The 2 arms (randomized at the level of health care provider) will be: 1. usual practice; 2.
- Conditions
- Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Human Papilloma Virus Infection Type 6
- Trial name
- NCT02558803
- Testing
- Simple Reminder
- Where
- 5 sites in United States
- Volunteers
- 1,305 people
- Sponsor
- Regenstrief Institute, Inc.
Polycystic Ovary Syndrome
Effect of Ultrasound Acupoints on Patients With Polycystic Ovary Syndrome
This study will be conducted to evaluate the effect of ultrasound acupoints on menstrual irregularity and hormone levels on polycystic ovary syndrome (PCOS) patient.
- Trial name
- NCT06844903
- Testing
- Pulsed ultrasound at acupuncture points, Standard care program
- Where
- Egypt
- Volunteers
- 44 people
- Sponsor
- Kafrelsheikh University
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This is a Phase I/Ib dose escalation, dose expansion, study to evaluate the safety and identify the recommended dose of modified immune cells PRGN-3005 (autologous chimeric antigen receptor (CAR) T cells developed by Precigen…
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT03907527
- Testing
- PRGN-3005 UltraCAR-T cells
- Where
- 2 sites in United States
- Volunteers
- 71 people
- Sponsor
- Precigen, Inc
Ovarian Cancer
Niraparib as Maintenance Treatment in Platinum Responsive Ovarian Cancer Patients: a Real Life Study
This is an observational phase IV study evaluating Niraparib as maintenance treatment in patients with platinum sensitive, platinum responsive, recurrent ovarian cancer in a real life setting.
- Trial name
- MITO 34 (NCT04617470)
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Polycystic Ovary Syndrome
AMH, Glucose Intolerance and Metabolic Syndrome in PCOS
Association between serum anti-Mullerian hormone (AMH) level and prevalence of glucose intolerance and metabolic syndrome in women with polycystic ovary syndrome (PCOS)
- Trial name
- NCT02676518
- Testing
- serum
- Where
- Thailand
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.